Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2019. Please click here to review Harrow Health’s complementary Letter to Stockholders for the third quarter 2019.
Mark L. Baum, CEO of Harrow Health, commented, “The third quarter of 2019 brought new records for our core ophthalmology business, as well as record high gross margins and Adjusted EBITDA. We’ve resolved various legal matters, normalized our cost structure, and completed the restructuring of our pharmaceutical compounding business, which is now sustainably profitable, setting the stage for our march towards our $100 million revenue run rate target in 2021 and 70% gross margins – which should produce about $1 per share of annualized adjusted earnings. All of these items and more, along with our plans in 2020, are elaborated on in our Letter to Stockholders.”
Conference Call and Webcast
The company’s management team will host a question and answer conference call with analysts and an audio-only webcast Wednesday at 5:00 p.m. Eastern Standard Time / 2:00 p.m. Pacific Standard Time. To participate, please use the dial in or click on the link below:
- U.S. callers: (844) 602-0380
- International callers: (862) 298-0970
- Audio-only webcast: please click here
Conference Call Replay:
A dial in replay of the call will be available until December 13, 2019. The webcast replay will be available until February 13, 2020.
- U.S. callers: (877) 481-4010, Replay ID: 55904
- International callers: (919) 882-2331, Replay ID: 55904
- Webcast: please click here
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.